Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IB Study of FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

NCT01413022 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT01413022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01413022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IB Study of FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Lead sponsor
Washington University School of Medicine
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2012
Completion date
September 30, 2016
Enrollment
44 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic neoplasms